Navigation Links
Respiratory Update: Interpreting Minimal Clinically Important Differences in COPD and Demonstrating Product Value with PROs, a New Life Science webinar Hosted by Xtalks
Date:11/25/2013

Toronto, Canada (PRWEB) November 25, 2013

Pharmaceutical companies face the daunting task of getting new respiratory products approved and launched in a crowded marketplace. Two main challenges in respiratory clinical trials are; interpreting minimal clinically important differences (MCID) and designing a patient reported instrument to demonstrate a compound’s value. Both are critical in the approval of your compound as well as in post marketing activities.

To compete effectively in the respiratory market, it is critical to show the value of your product over the competition. One way to do this is to examine the effect of new products on patients using Patient Reported Outcomes (PROs).

Join esteemed speakers Dr. Chad Gwaltney, Senior Director of Consulting Services at ERT, and Dr. Kai-Michael Beeh, Founder and Medical Director at insaf Respiratory Research Institute, as they examine MCIDs and different types of PROs that are available for respiratory diseases and review case studies of successful demonstrations of product value in respiratory programs.

For more information on this webinar or to register, visit: http://xtalks.com/Respiratory-Update-COPD-Product-value-and-PROs.ashx.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx.

Contact:
Michelle Tran (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11363239.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Anesthesia and Respiratory Devices Market is Expected to Reach USD 21.6 Billion Globally in 2019: Transparency Market Research
2. Europe Anesthesia and Respiratory Devices Market Outlook to 2018 - Respiratory Devices, Respiratory Measurement Devices, Anesthesia Machines, Sleep Apnea Diagnostic Systems, Pain Management Devices and Others
3. Newly-Published Study Compares SURFAXIN LS™ and CUROSURF® in Well-Established Model of Respiratory Distress Syndrome
4. Southeast Asia Drug and Medical Device Update: Market Potential and Regulatory Environment, New Life Science Webinar Hosted by Xtalks
5. Patent Bar Exam Update: New Information Tested and More Changes to Come
6. Research update: Chips with self-assembling rectangles
7. QuantRx® Biomedical Provides Corporate Update: Focused on Diagnostics and Feminine Hygiene Segments
8. Minimally Invasive Devices Adds $2.5 Million to its Series B
9. US Minimally Invasive Spine Technology Market to Grow Strongly to $2 Billion by 2017
10. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
11. New England Biolabs Develops Novel Polymerase with Ultra-High Fidelity and Minimal GC Bias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... the deadline to participate in its previously announced ... consisting of shares of common stock and Series ... holders of listed warrants. As ...
(Date:2/24/2017)... 2017  Driven by consumers, preference towards more ... fastest growing categories, finds the recently published U.S. ... Care: Multi-regional Market Analysis and Opportunities study ... Kline. "Biotechnology actives are derived from ... effective for skin and hair care applications," explains ...
(Date:2/24/2017)... Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), ... announced its financial results for the fourth quarter and fiscal ... Highlights Total sales in the fourth ... increased by 13.6% in USD terms to $77.6 million from ... Gross profit increased by 13.3% to $46.8 million from ...
(Date:2/23/2017)... LONDON and NEW YORK ... at HIMSS, Lumeon , a leading digital ... (DN Telehealth), a provider of telemedicine and remote ... care pathways for telemedicine reimbursements.  ... and their patients, in real-time, extending consultations beyond ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):